Translate Register Log In Login with facebookLogin and Register

Colitis treated by activated vitamin D getting into the colon via emulsion (mice) – July 2018

Therapeutic effect of vitamin D3-containing nanostructured lipid carriers on inflammatory bowel disease.

J Control Release. 2018 Jul 12. pii: S0168-3659(18)30413-9. doi: 10.1016/j.jconrel.2018.07.019. [Epub ahead of print]
Zai K1, Hirota M2, Yamada T2, Ishihara N2, Mori T3, Kishimura A4, Suzuki K2, Hase K5, Katayama Y6.


Much more benefit when a drug can be delivered exactly to where it is needed
Much better than increasing Vitamin D levels for the entire body
Other examples for Vitamin D targeted delivery include topical for skin and oral for gums
Respiratory vitamin D (inhaled) looks very promising

See also VitaminDWiki


Activated Vitamin D

click on chart for details

  • Gut problems result in reduced absorption of Vitamin D, Magnesium, etc.
  • Celiac disease has a strong genetic component.
    • Most, but not all, people with celiac disease have a gene variant.
    • An adequate level vitamin D seems to decrease the probability of getting celiac disease.
    • Celiac disease causes poor absorption of nutrients such as vitamin D.
    • Bringing the blood level of vitamin D back to normal in patients with celiac disease decreases symptoms.
    • The prevalence of celiac disease, not just its diagnosis, has increased 4X in the past 30 years, similar to the increase in Vitamin D deficiency.
  • Review in Nov 2013 found that Vitamin D helped
    Many intervention clinical trials with vitamin D for Gut problems (101 trials listed as of Sept 2019)
  • All items in category gut and vitamin D 145 items

PDF is available free at Sci-Hub  10.1016/j.jconrel.2018.07.019

Spleen was not as enlarged with activiated vitamin D emulsion

The active form of vitamin D3, 1,25(OH)2D3 has been found to exert multiple effects on the suppression of progression of inflammatory bowel disease (IBD). Vitamin D3 has been gathering attention as a therapy for IBD. However, the clinical trials conducted to date revealed that a relatively high dosage of vitamin D3 was required to see a significant therapeutic effect. Thus, effective formulation and delivery of vitamin D3 to colonic inflammatory lesions will be required. Herein we describe the preparation of a nanostructured lipid carrier (NLC) for the encapsulation of 1,25(OH)2D3 for colonic delivery via oral administration. The optimized fabrication procedure enabled the incorporation of 1,25(OH)2D3 in the NLC by minimizing the destruction of chemically unstable 1,25(OH)2D3. The obtained NLCs orally delivered 1,25(OH)2D3 to the colon in mice and maintained a high concentration of 1,25(OH)2D3 in the colonic tissue for at least 12 h. The NLC showed multiple effects on the suppression of symptoms of colitis induced by dextran sodium sulfate, namely maintaining crypt structure, reducing the tissue concentration of inflammatory cytokines, suppressing the infiltration of polymorphonuclear leukocytes, and augmenting anti-inflammatory CX3CR1high macrophages. Our NLCs containing 1,25(OH)2D3 may be an alternative treatment for IBD therapy.

Created by admin. Last Modification: Tuesday July 24, 2018 00:53:20 GMT-0000 by admin. (Version 8)

Attached files

ID Name Comment Uploaded Size Downloads
10236 Splene colitis.jpg admin 24 Jul, 2018 00:26 9.09 Kb 108
See any problem with this page? Report it (FINALLY WORKS)